Clinical trial

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

NCT00095225

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Avastin (bevacizumab) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Tarceva (erlotinib HCl) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2004-07-01

PhasePHASE2

Conditions

Non-Small-Cell Lung Carcinomaunresolved

Neoplasm Recurrence, Localunresolved

Interventions

Avastin (bevacizumab)DRUG

Tarceva (erlotinib HCl)DRUG

Sponsors & collaborators

Genentech, Inc.lead sponsor

Mapped research locations

ChicagoIllinois, United States2 PortlandOregon, United States2 OrlandoFlorida, United States2 MemphisTennessee, United States2 HoustonTexas, United States1 Los AngelesCalifornia, United States1 SeattleWashington, United States1 PittsburghPennsylvania, United States1 San DiegoCalifornia, United States1 OmahaNebraska, United States1 Las VegasNevada, United States1 New OrleansLouisiana, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00095225 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.